Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.gsk-india.com | |
Market Cap | 21,372.27 Cr. | |
Enterprise Value(EV) | 20,672.35 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 99.29 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 12.74 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.90 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 85.88 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 14.73 | Calculated using Price: 1,264.95 |
Dividend Yield | 7.13 | Period Ending 2022-03 |
No. of Shares Subscribed | 16.94 Cr. | 169,406,034 Shares |
FaceValue | 10 | |
Company Profile | ||
The company is engaged in research, manufacture and make available a broad range of medicines and vaccines that benefit people. The company's Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in anti-infectives and dermatology. Its R&D approach focuses on science related to the immune system, use of genetics and advanced technologies. Meanwhile, Its Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. The company is the leaders in India in the private segment. |
1 Day |
|
+0.16% |
1 Week |
|
-1.96% |
1 Month |
|
-4.92% |
3 Month |
|
-7.50% |
6 Month |
|
-12.61% |
1 Year |
|
-22.59% |
2 Year |
|
-13.89% |
5 Year |
|
+3.06% |
10 Year |
|
+22.47% |
9 years | 2013-12 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 24.10 | 24.95 | 18.75 | 16.08 | 17.26 | 21.22 | 4.71 | 17.42 | 18.39 | |
Return on Capital Employed (%) | 35.54 | 39.53 | 28.81 | 24.39 | 26.56 | 32.54 | 15.76 | 27.74 | 37.72 | |
Return on Assets (%) | 15.95 | 15.44 | 7.84 | 5.16 | 4.93 | 5.77 | 1.72 | 9.52 | 10.11 |
Particulars | 10 years | 2013-12 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 1,990 | 1,829 | 2,183 | 2,007 | 2,057 | 2,140 | 1,821 | 1,478 | 2,663 | 1,455 | |
Non Curr. Liab. | 159 | 197 | 3,498 | 3,700 | 2,632 | 2,860 | 180 | 179 | 159 | 145 | |
Curr. Liab. | 889 | 1,107 | 784 | 881 | 2,949 | 2,804 | 1,022 | 1,355 | 1,698 | 1,295 | |
Minority Int. | |||||||||||
Equity & Liab. | 3,037 | 3,133 | 6,465 | 6,588 | 7,639 | 7,804 | 3,023 | 3,012 | 4,520 | 2,895 | |
Non Curr. Assets | 413 | 546 | 4,087 | 4,753 | 4,103 | 4,445 | 1,248 | 809 | 812 | 700 | |
Curr. Assets | 2,624 | 2,587 | 2,378 | 1,835 | 3,536 | 3,359 | 1,775 | 2,203 | 3,708 | 2,195 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 3,037 | 3,133 | 6,465 | 6,588 | 7,639 | 7,804 | 3,023 | 3,012 | 4,520 | 2,895 |
Particulars | 10 years | 2013-12 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 2,608 | 3,363 | 2,838 | 2,908 | 2,871 | 3,128 | 3,224 | 2,926 | 3,278 | 3,288 | |
Other Income | 222 | 259 | 123 | 73 | 55 | 102 | 79 | 111 | 76 | 79 | |
Total Income | 2,830 | 3,622 | 2,961 | 2,982 | 2,926 | 3,230 | 3,303 | 3,036 | 3,354 | 3,366 | |
Total Expenditure | -2,124 | -2,788 | -2,360 | -2,489 | -2,366 | -2,527 | -2,567 | -2,327 | -2,516 | -2,509 | |
PBIDT | 706 | 833 | 601 | 492 | 560 | 703 | 736 | 709 | 838 | 858 | |
Interest | 0 | 0 | 0 | 0 | 0 | -1 | -6 | -4 | -2 | -2 | |
Depreciation | -20 | -25 | -25 | -26 | -38 | -49 | -83 | -79 | -68 | -65 | |
Taxation | -230 | -279 | -202 | -174 | -189 | -237 | -213 | -167 | -398 | -409 | |
Exceptional Items | 26 | -52 | 2 | 46 | 18 | 29 | -341 | -173 | 12 | 12 | |
PAT | 482 | 476 | 376 | 337 | 351 | 445 | 93 | 287 | 381 | 393 | |
Minority Interest | |||||||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 482 | 476 | 376 | 337 | 351 | 445 | 93 | 358 | 1,695 | 1,682 | |
Adjusted EPS | 28 | 28 | 22 | 20 | 21 | 26 | 6 | 21 | 100 | 99 |
Particulars | 10 years | 2012-12 Rs. Cr. | 2013-12 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 314 | 281 | 338 | 139 | 234 | 473 | 409 | 491 | 578 | 811 | |
Cash Fr. Inv. | -110 | 189 | 180 | 499 | 301 | -104 | -153 | -57 | 418 | -406 | |
Cash Fr. Finan. | -441 | -494 | -497 | -638 | -511 | -307 | -358 | -428 | -696 | -524 | |
Net Change | -237 | -24 | 21 | 0 | 24 | 62 | -102 | 6 | 300 | -119 | |
Cash & Cash Eqvt | 138 | 114 | 116 | 115 | 139 | 201 | 99 | 105 | 405 | 286 |
Wed, 11 Jan 2023
Board Meeting Intimation for Un- Audited Financial Results For The Third Quarter & Nine Months Ended 31St December 2022 GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2023 inter alia to consider and approve Un- Audited Financial Results for the third quarter & nine months ended 31st December 2022 |
Fri, 06 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate pursuant to Regulation 74(5) |
Thu, 29 Dec 2022
Closure of Trading Window Closure of Trading window |
Fri, 27 Jan 2023 |
|
|
|
|
|